COMPARING EFFICACY OF THE ANTIBIOTICS CONSIDERING NEW AGENTS USED TO TREAT ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY MRSA: A NETWORK META-ANALYSIS

Acute bacterial infections of the skin and skin tissues (ABSSSIs(, especially methicillin-Resistant Staphylococcus Aureus (MRSA) type, cause many problems for the patient. This Network Meta-Analysis (NMA) was designed to compare the efficacy between vancomycin and other antibiotics to determine a better treatment to resolve skin infections.

Appropriate NMA studies were searched in the Cochrane central register of controlled trials, Embus, and Medline databases until January 2021. The Random effects model was used for each outcome in the NMA. The well-known PICOS17 strategy was used to search for articles. Descriptive or non-randomized studies, studies without specific outcomes or characteristics of ABSSSIs, review studies, and studies with subgroup analysis or information without the desired intervention were excluded from the study.

26 randomized controlled trials with 16031 patients met the inclusion criteria. The results of NMA showed that the efficacy of ceftaroline fusamil, delafloxacin, GNGQ2, linezolid, omadacycline, Tigecyclin, and vancomycin-aztreonam were higher than the standard treatment, and the glycopeptides of dalbavancin, oritavancin, and telavancin are not significantly different from them. In the case of MRSA infections, Tedizolid, Linezolid, dalbavancin, and vancomycin-Linezolid therapy were shown to be more effective than the standard therapy.

It could be concluded that due to some known advantages of glycopeptides and that they are not inferior to vancomycin in terms of efficacy, these drugs can be a good alternative to vancomycin.